HealthDay - THURSDAY, June 30 (HealthDay News) -- The cost of Provenge, an expensive and newly approved therapeutic prostate cancer vaccine, will be covered by Medicare for men with metastatic prostate cancer, the agency announced late Thursday.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.